BCAT1 inhibition significantly impaired growth of BCR/TLR9 pathway–dependent MDC DLBCL xenografts in vivo, identifying BCAT1 as a promising B cell lymphoma therapeutic target. This evidence concerns the gene TLR9 and B-cell non-Hodgkin lymphoma.